Recombinant hepatitis B vaccine market is expected to grow at a CAGR of 5.6% during the forecast period (2022-2028). The rising incidence of acute and chronic hepatitis B infections across the globe is driving market growth. There is an increased demand for recombinant HBV vaccines 10mcg/ml and 10 mcg/0.5 ml, which provide long-lasting protection against chronic hepatitis B infection. The Hepatitis B vaccine is a preventative vaccine for hepatitis B. It's a shot that's administered to the arm or thigh. It works by causing the body to develop virus immunity.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/recombinant-hepatitis-b-vaccine-market
The increasing prevalence of chronic HBV infections, rising awareness about vaccination programs, and rising demand for preventive vaccines are some factors driving the global recombinant hepatitis B vaccine market. In addition, the vaccine manufacturers have been significantly focusing on the development of novel recombinant hepatitis B vaccines. North America is expected to hold a significant share in the market owing to the rising number of chronic HBV cases in the region. The Latin America recombinant hepatitis B vaccine market is driven by the rising focus on the prevention and treatment of HBV infection in the region. Further, owing to the rising incidence of HBV infections and growing awareness about vaccination programs in the region, Asia Pacific is expected to witness lucrative growth in the global recombinant hepatitis B vaccine market.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Type
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Merck & Co., Inc., GlaxoSmithKline plc, and Pfizer Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Recombinant Hepatitis B Vaccine Market Report by Segment
By Type
- 10mcg/ml
- 10mcg/0.5ml
By Application
- Newborn/Children
- Adult
A full report of Recombinant Hepatitis B Vaccine Market is available at: https://www.omrglobal.com/industry-reports/recombinant-hepatitis-b-vaccine-market
Recombinant Hepatitis B Vaccine Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Bharat Biotech International Ltd.
- CSL Ltd.
- Dynavax Technologies Corp
- Emergent BioSolutions Inc.
- GlaxoSmithKline PLC
- KM Biologics (Meiji Holdings Co., Ltd.)
- LG Chem Ltd.
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- Serum Institute of India Pvt., Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research